@article {Lewis2022.02.14.22270934, author = {HC Lewis and H Ware and M Whelan and L Subissi and Z Li and X Ma and A Nardone and M Valenciano and B Cheng and K Noel and C Cao and M Yanes-Lane and B Herring and A Talisuna and N Nsenga and T Balde and DA Clifton and M Van Kerkhove and DL Buckeridge and N Bobrovitz and J Okeibunor and RK Arora and I Bergeri and the UNITY Studies Collaborator Group}, title = {SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021}, elocation-id = {2022.02.14.22270934}, year = {2022}, doi = {10.1101/2022.02.14.22270934}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Introduction Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges in contact tracing, routine surveillance systems and laboratory testing capacities and strategies. We undertook a meta-analysis of population-based seroprevalence studies to estimate SARS-CoV-2 seroprevalence in Africa to inform evidence-based decision making on Public Health and Social Measures (PHSM) and vaccine strategy.Methods We searched for seroprevalence studies conducted in Africa published 01-01-2020 to 30-12-2021 in Medline, Embase, Web of Science, and Europe PMC (preprints), grey literature, media releases and early results from WHO Unity studies. All studies were screened, extracted, assessed for risk of bias and evaluated for alignment with the WHO Unity protocol for seroepidemiological investigations. We conducted descriptive analyses of seroprevalence and meta-analysed seroprevalence differences by demographic groups, place and time. We estimated the extent of undetected infections by comparing seroprevalence and cumulative incidence of confirmed cases reported to WHO. PROSPERO: CRD42020183634.Results We identified 54 full texts or early results, reporting 151 distinct seroprevalence studies in Africa Of these, 95 (63\%) were low/moderate risk of bias studies. SARS-CoV-2 seroprevalence rose from 3.0\% [95\% CI: 1.0-9.2\%] in Q2 2020 to 65.1\% [95\% CI: 56.3-73.0\%] in Q3 2021. The ratios of seroprevalence from infection to cumulative incidence of confirmed cases was large (overall: 97:1, ranging from 10:1 to 958:1) and steady over time. Seroprevalence was highly heterogeneous both within countries - urban vs. rural (lower seroprevalence for rural geographic areas), children vs. adults (children aged 0-9 years had the lowest seroprevalence) - and between countries and African sub-regions (Middle, Western and Eastern Africa associated with higher seroprevalence).Conclusion We report high seroprevalence in Africa suggesting greater population exposure to SARS-CoV-2 and protection against COVID-19 disease than indicated by surveillance data. As seroprevalence was heterogeneous, targeted PHSM and vaccination strategies need to be tailored to local epidemiological situations.Competing Interest StatementCompeting interests: WHO had a role in study design, data collection, data analysis, data interpretation, and writing of the report. No other funders had any such role. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication. Potential other competing interests of named co-authors include: RKA reports personal fees from the Public Health Agency of Canada and the Bill and Melinda Gates Foundation Strategic Investment Fund, as well as equity in Alethea Medical (Outside the submitted work). MPC reports personal fees from GEn1E Lifesciences (Outside the submitted work), nplex biosciences (Outside the submitted work), Kanvas biosciences (Outside the submitted work). JP reports grants from MedImmune (Outside the submitted work) and Sanofi-Pasteur (Outside the submitted work), grants and personal fees from Merck (Outside the submitted work) and AbbVie (Outside the submitted work), and personal fees from AstraZeneca (Outside the submitted work). CCo reports funding from Sanofi Pasteur (Outside of the submitted work). Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=183634 Funding StatementWHO Solidarity Response Fund and the German Federal Ministry of Health COVID-19 Research and Development. SeroTracker (led by RKA, including MW, HW, ZL, XM, CC, MYL, DB, JP, MPC, ML, MS, GRD, NI, CZ, SP, HPR, TY, KCN, DK, SAA, ND, CD, NAD, EL, RKI, ASB, ELB, AS, JC and NB) report funding from WHO, Canada COVID-19 Immunity Task Force through the Public Health Agency of Canada, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review and meta-analysis of publicly available observational studies (available in reference list)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetailed information on each study is available in Supplement S4.2 and references are cited in the Supplementary File (S4.4). Primary seroprevalence estimates and statistical code relevant to the study are available in a public, open access repository: https://github.com/serotracker/Africa-SRMA-seroprevalence/tree/1a7e88ed2679d4027092b2898cf7048426e8b1b6 Seroprevalence estimates by age and sex subgroups relevant to the study are uploaded to Zenodo by UNITY study collaborators and DOIs for each included Zenodo study are cited in the Supplementary File (S4.4). Data are available to download upon reasonable request. https://zenodo.org/communities/unity-sero-2021?page=1\&size=20. https://zenodo.org/communities/unity-sero-2021/?page=1\&size=20}, URL = {https://www.medrxiv.org/content/early/2022/02/15/2022.02.14.22270934}, eprint = {https://www.medrxiv.org/content/early/2022/02/15/2022.02.14.22270934.full.pdf}, journal = {medRxiv} }